309 related articles for article (PubMed ID: 36366846)
1. Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy.
Dardiotis E; Kyriakides T
Curr Neuropharmacol; 2023; 21(3):471-481. PubMed ID: 36366846
[TBL] [Abstract][Full Text] [Related]
2. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.
Carroll A; Dyck PJ; de Carvalho M; Kennerson M; Reilly MM; Kiernan MC; Vucic S
J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):668-678. PubMed ID: 35256455
[TBL] [Abstract][Full Text] [Related]
3. Hereditary transthyretin amyloidosis overview.
Manganelli F; Fabrizi GM; Luigetti M; Mandich P; Mazzeo A; Pareyson D
Neurol Sci; 2022 Dec; 43(Suppl 2):595-604. PubMed ID: 33188616
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.
Sekijima Y; Ueda M; Koike H; Misawa S; Ishii T; Ando Y
Orphanet J Rare Dis; 2018 Jan; 13(1):6. PubMed ID: 29343286
[TBL] [Abstract][Full Text] [Related]
5. Hereditary transthyretin-related amyloidosis.
Finsterer J; Iglseder S; Wanschitz J; Topakian R; Löscher WN; Grisold W
Acta Neurol Scand; 2019 Feb; 139(2):92-105. PubMed ID: 30295933
[TBL] [Abstract][Full Text] [Related]
6. Transthyretin Variant Amyloidosis with a TTR A97D (p.A117D) Mutation Manifesting Remarkable Asymmetric Neuropathy.
Ikeda K; Yamamoto D; Usui K; Takeuchi H; Oka N; Katoh N; Yazaki M; Kametani F; Nishino I; Hisahara S
Intern Med; 2023 Aug; 62(15):2261-2266. PubMed ID: 36543209
[TBL] [Abstract][Full Text] [Related]
7. The neuropathy in hereditary transthyretin amyloidosis: A narrative review.
Tozza S; Severi D; Spina E; Iovino A; Aruta F; Ruggiero L; Dubbioso R; Iodice R; Nolano M; Manganelli F
J Peripher Nerv Syst; 2021 Jun; 26(2):155-159. PubMed ID: 33960565
[TBL] [Abstract][Full Text] [Related]
8. [Gene therapy options for hereditary transthyretin-related amyloidosis].
Schilling M
Nervenarzt; 2022 Jun; 93(6):557-565. PubMed ID: 35419654
[TBL] [Abstract][Full Text] [Related]
9. Neuropathy Associated with Systemic Amyloidosis.
Kaku M; Berk JL
Semin Neurol; 2019 Oct; 39(5):578-588. PubMed ID: 31639841
[TBL] [Abstract][Full Text] [Related]
10. A novel TTR mutation (p.Ala65Val) underlying late-onset hereditary transthyretin (ATTRv) amyloidosis with mixed cardiac and neuropathic phenotype: a case report.
Thimm A; Oubari S; Hoffmann J; Carpinteiro A; Papathanasiou M; Luedike P; Kessler L; Rischpler C; Röcken C; Diebold I; Rassaf T; Schmidt H; Kleinschnitz C; Hagenacker T
BMC Neurol; 2022 Dec; 22(1):469. PubMed ID: 36494773
[TBL] [Abstract][Full Text] [Related]
11. Transthyretin Amyloidosis Presenting With Upper-Extremity Neuropathy and Paucity of Autonomic Impairment.
Devarapalli S; Zhou DJ; Dyck PJB; Piccione EA
J Clin Neuromuscul Dis; 2019 Jun; 20(4):207-209. PubMed ID: 31135624
[TBL] [Abstract][Full Text] [Related]
12. Amyloid Neuropathy: From Pathophysiology to Treatment in Light-Chain Amyloidosis and Hereditary Transthyretin Amyloidosis.
Chompoopong P; Mauermann ML; Siddiqi H; Peltier A
Ann Neurol; 2024 Jun; ():. PubMed ID: 38923548
[TBL] [Abstract][Full Text] [Related]
13. Three patients of transthyretin amyloidosis in a Japanese family with amyloidogenic transthyretin Thr49Ser (p.Thr69Ser) variant.
Ikura H; Kitakata H; Endo J; Moriyama H; Sano M; Tsujikawa H; Sawano M; Masuda T; Ohki T; Ueda M; Kosaki K; Fukuda K
Eur J Med Genet; 2022 Mar; 65(3):104451. PubMed ID: 35149236
[TBL] [Abstract][Full Text] [Related]
14. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
15. Red flags and adjusted suspicion index for distinguishing hereditary transthyretin amyloid polyneuropathy from idiopathic axonal polyneuropathy.
Warendorf JK; van der Star GM; Dooijes D; Notermans NC; Vrancken AFJE
Neurol Sci; 2023 Oct; 44(10):3679-3685. PubMed ID: 37266816
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
Coelho T; Waddington Cruz M; Chao CC; Parman Y; Wixner J; Weiler M; Barroso FA; Dasgupta NR; Jung SW; Schneider E; Viney NJ; Dyck PJB; Ando Y; Gillmore JD; Khella S; Gertz MA; Obici L; Berk JL
Neurol Ther; 2023 Feb; 12(1):267-287. PubMed ID: 36525140
[TBL] [Abstract][Full Text] [Related]
17. Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology.
Sekijima Y; Hammarström P; Matsumura M; Shimizu Y; Iwata M; Tokuda T; Ikeda S; Kelly JW
Lab Invest; 2003 Mar; 83(3):409-17. PubMed ID: 12649341
[TBL] [Abstract][Full Text] [Related]
18. A natural history analysis of asymptomatic
Coelho T; Conceição I; Waddington-Cruz M; Keohane D; Sultan MB; Chapman D; Amass L;
Amyloid; 2022 Dec; 29(4):228-236. PubMed ID: 35730447
[TBL] [Abstract][Full Text] [Related]
19. Clinical and pathological findings in familial amyloid polyneuropathy caused by a transthyretin E61K mutation.
Murakami T; Nishimura H; Nagai T; Hemmi S; Kutoku Y; Ohsawa Y; Sunada Y
J Neurol Sci; 2017 Oct; 381():55-58. PubMed ID: 28991715
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
